Dr. Roberto TAKAOKA’s visit to Manaus launches a vital new support network while opening doors to unique environmental research on atopic dermatitis. Last month, Dr Roberto TAKAOKA, Vice-President of ISAD, visited Manaus in the heart of Brazil’s Amazon region as part of a project by the Brazilian Atopic Dermatitis Association (AADA) to establish new support […]
Read More
The success of the second call for the ISAD-GADA Fellowship was highlighted, with seven applicants from six different countries (Ethiopia, Ghana, Lebanon, Madagascar, Malaysia and Nepal). A heartfelt thank you to everyone who applied. We were genuinely encouraged by the volume and quality of submissions we received. We are delighted to inform that Dr Naina […]
Read More
From “Response” to “Reassurance” Topical corticosteroids (TCS) remain the cornerstone of atopic dermatitis (AD) management worldwide. Yet, despite decades of clinical use, a paradox persists: while clinicians rely on TCS as first-line therapy, many patients remain uncertain, and sometimes fearful, about how to use them safely over time. This tension is increasingly visible in discussions […]
Read More
New Strategic Partnership The International Society of Atopic Dermatitis (ISAD) is proud to announce a new exclusive strategic partnership with Umer Doctor, China’s premier professional platform for dermatologists. This collaboration marks a significant milestone as we prepare for the 16th Georg RAJKA International Symposium on Atopic Dermatitis, taking place in Beijing. Why This Partnership Matters […]
Read More
Fast runners or long-distance champions? Rethinking AD therapy trajectories➜ DOI: 10.1111/all.70395A new Allergy editorial proposes an athletic metaphor for AD therapies: JAK inhibitors as “sprinters,” IL-4/IL-13 biologics as “mid-distance runners,” and emerging immune-resetting approaches as “marathoners.” An attractive framework—but perhaps the key question is not only how therapies run, but how disease evolves in each patient. [...] Read More
Pediatric Atopic Dermatitis Guidelines in 2026:Convergence of Evidence, Divergence of Practice The recent JAAD 2026 guidelines on pediatric atopic dermatitis DOI: 10.1016/j.jaad.2026.02.114, led by the late Robert Sidbury, marks an important milestone: it is the first fully evidence-graded, pediatric-specific update in the era of biologics and JAK inhibitors. Built on a strict GRADE methodology and largely restricted […]
Read MoreAI-Powered Atopic Dermatitis Assessment: Patients Can Contribute + Small punch biopsies and non-negative matrix factorization (NMF) to study AD transcriptome + An important role of IL-22 in Th2 driven acute AD in epidermal reconstructs models + Health-Related Quality of Life in AD and Psoriasis: Are There Distinct Psychological Traits? + Towards a scientific approach of traditional Chinese medicine formulas
Read More
Are you under 30 35 and ready to prove your expertise in Atopic Dermatitis? The RAJKA-ISAD Symposium is calling all residents, fellows, and early-career practitioners (ECP) to step out of the clinic and into the arena. We are launching “The AD Masterminds”—a high-stakes, high-energy team tournament designed to crown the future leaders of AD care. […]
Read More
A New Chapter in International Partnership The International Society of Atopic Dermatitis (ISAD) is pleased to announce the establishment of a The International Society of Atopic Dermatitis (ISAD) and the European Academy of Allergy and Clinical Immunology (EAACI) are proud to announce a formal strategic partnership, cemented by a Memorandum of Understanding signed in February […]
Read More
Beyond the “All-TH2” Paradigm in Atopic Dermatitis For more than two decades, atopic dermatitis (AD) has largely been interpreted through the framework of type-2 immunity. IL-4, IL-13, IgE, and eosinophils became the canonical pathway explaining disease pathogenesis and guiding therapeutic development. The remarkable clinical success of IL-4/IL-13 blockade has reinforced this paradigm. Yet both the […]
Read More